Novo Nordisk’s Wegovy gets MHRA nod for use to lower heart risks
Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Cardiovascular disease
GLP-1R agonist withdrawal effect on weight loss and cardiovascular risks remains unmet need:…
Zepbound is Eli Lilly’s new glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist, approved by the FDA…
Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData
The latest data from the final analysis of the Phase II OCEAN(a)-DOSE study showed that olpasiran reduced Lp(a) levels in patients…
Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per…
With approval, Empagliflozin would become the first and only clinically-proven therapy to improve outcomes for the full spectrum…